Connect with us

Cannabis News

Senator Blocks Confirmation Of Trump’s ‘Unqualified’ White House Drug Czar Pick Who Has Voiced Medical Marijuana Support

Published

on

A Democratic senator is holding back nearly 90 of President Donald Trump’s administration nominees, including the president’s pick for White House drug czar He says he is among many “unqualified” candidates who threaten to “undermine the rule of law and our national security.”

The Senate Judiciary Committee in October advanced the nomination of Sara Carter Bailey to join the administration as director of the Office of National Drug Control Policy (ONDCP). But when he was included in an en bloc confirmation package of 88 nominees, Sen. Michael Bennet (D-CO) raised a procedural question that led Republicans to stall the vote.

“I’ve just blocked 88 of Trump’s nominees for confirmation, including Sara Carter Bailey, the former Fox News contributor nominated to be our country’s drug czar,” Bennet said Thursday. “Bailey was nominated by Trump, who recently pardoned the former president of Honduras, who served 45 years in prison for conspiring to distribute more than 400 tons of cocaine.”

“I will not allow those without a candidate, this White House or the president to undermine the rule of law and our national security,” he said. he said.




The procedural complaint raised by Bennet relates to the ONDCP director being a “Tier I” executive officer.

Therefore, unlike the other candidates in the package, Bailey could not be included in the group vote – the body that was chaired by the Republican senator on Thursday. recognize.

Bailey, for his part, yes expressed his support for medical cannabis, while stating that he has “no problem” with legalizationeven if you may not personally agree with the policy.

A former journalist known for his coverage of drug cartels, Bailey also recently informed senators that the administration. keeping “all options” on the table as it continues to consider a proposal to reorganize marijuanawhile describing cannabis reform as a “bipartisan issue.”

Bennet isn’t the only senator questioning the nominee’s abilities. Before the committee’s vote in October, Sen. Dick Durbin (D-IL), the panel’s ranking member, called Bailey a Trump “loyalist” who was “appointed to a position that he is completely, utterly unqualified for.”

“He’s not a doctor or an addiction specialist,” she said. “He’s never been a prosecutor or a law enforcement officer.”

Given the ONDCP director’s role in setting and carrying out the administration’s agenda on drug policy issues, Bailey’s enthusiastic endorsement of medical cannabis in the past is welcome to advocates.

Senator Cory Booker (D-NJ) raised the issue of cannabis rescheduling one-on-one with the candidate in September, stating that the proposal to move marijuana from Schedule I to III of the Controlled Substances Act (CSA) would be a “step in the right direction.”

“It would open the door to more scientific research, so if you were to be confirmed, how would you advise the American president on the reprogramming process going on?” he asked.

Bailey said she shares Booker’s passion for the issue, which she described as “bipartisan.”

“If confirmed as director, I will comply with all federal laws and meet all legal responsibilities of ONDCP,” he said. “However, we will continue to work in depth with research and data. We will continue to do so and explore all options.”

Trump endorsed the redistricting on the campaign trail before his second term — as well as bank access to the marijuana industry and a ballot initiative to legalize Florida. But his latest comments in late August about the timing of the reorganization decision gave a more ambiguous impression of his stance on the matter.

While Bailey has spoken often on a variety of marijuana policy issues (focusing on illegal trafficking and illegal growing operations on US soil, for example), his public comments have been limited on how he personally feels about the issue. Last year, she said in an episode of her podcast, The Sara Carter Show, that she makes a distinction between legally regulated and illegally supplied marijuana.

“I don’t have a problem if it’s legalized and controlled,” he said. “I mean, maybe I have my own issues with how I feel about it, but I think it’s a wonderful way to handle cannabis for medicine and medical reasons — especially for people with cancer and other diseases, you know — to manage the disease and the side effects of those drugs and diseases. So I’m not saying we should make it illegal.”

If Bailey is ultimately confirmed by the Senate, he will be the second drug czar to come out in favor of medical marijuana. Former President Joe Biden’s ONDCP Director Rahul Guptaworked as a consultant to cannabis businesses and oversaw the implementation of West Virginia’s medical marijuana program.

On his social media, Bailey has previously shared links (without comment) to news on various marijuana-related topics. In addition to his increased focus on illegal billboards, he has also published on congressional and state legalization votes, Biden administration staffers fired for cannabis use, Democratic presidential candidates’ support for legalization, progress on cannabis banking legislation in Congress, and state policy developments such as the legalization of cannabis cafes in Alaska.

the federal statute The drug czar is prohibited from agreeing to the legalization of Schedule I drugs in the CSA, including marijuana.

“The Director . . . shall ensure that federal funds appropriated to the Office of National Drug Control Policy shall not be expended for any study or contract related to the legalization (for medical use or any other use) of a substance listed in section I of section 812 of this title and shall take such measures as may be necessary to oppose any attempt to legalize the use (in any form) of a substance not listed in subparagraph (I)(B) of section 8 of section (I). The purpose of the Food and Drug Administration approved for medical use.

In April, on the other hand, the democratic members of Congress announced the introduction of a bill that would remove this restriction. It has yet to advance in the GOP-controlled Congress.

Bailey has separately sounded the alarm about the risk of pesticides and other contaminants in marijuana grown and sold by Chinese cartels…recently a House committee took up the matter.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

Last year, the candidate discussed the issue with Derek Maltz, a now-retired Drug Enforcement Administration (DEA) official who is serving as the agency’s interim administrator before his confirmation. Trump’s perennial pick, Terrance Cole.

In an X post about the interview with Maltz, Bailey said how “Chinese marijuana growing operations are using dangerous chemicals as pesticides.”

In 2022, U.S. Representative Mike Garcia (R-CA) praised Bailey for working with his office to bring attention to illegal grow operations in his district, leading to an investigation by local law enforcement.

Bailey credited congress, saying, “The work you’ve done to get rid of illegal marijuana seeds has prevented the cartels from exploiting your community, the people forced to work in it, and (your money).”

In a 2021 interview with Fox News’ Sean Hannity, he also talked about his work with Garcia, including accompanying him on a helicopter, “a lot of sophisticated illegal farms worth billions of dollars.”

The posters “have become much bolder. They are not afraid to hide,” he said. “They don’t hide it because they don’t feel like they’ll ever be held accountable for it.”

In a sense, Bailey seems to be implicitly suggesting that he supports regulated access to cannabis as a means to promote public safety and health. Whether that implied position would influence federal policy and whether the role of ONDCP director is confirmed and assumed remains to be seen.

On his social media, he has previously shared links (without comment) to news on various marijuana-related topics. In addition to his increased focus on illegal billboards, he has also published on congressional and state legalization votes, Biden administration staffers fired for cannabis use, Democratic presidential candidates’ support for legalization, progress on cannabis banking legislation in Congress, and state policy developments such as the legalization of cannabis cafes in Alaska.

Photo by Chris Wallis // Side Pocket Images.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

Tilray Medical announces commercial launch of medical cannabis in Panama

Published

on

By

Tilray Medical has announced the launch of its first medical cannabis product in Panama, part of the company’s continued global expansion and commitment to improving patient access to pharmaceutical grade cannabinoids worldwide.

Following the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP certified production facilities in Portugal through a joint venture with Solana Life Group S. de RL, the Product is to be distributed through Farmacias Arrocha, one of the leading pharmaceutical chains in Panama, where patients will be able to access Tilray Oral Solution CBD with medical prescription100. This is expected to provide patients and healthcare professionals with access to regulated medical cannabis of pharmaceutical quality through established healthcare channels.

Rajnish Ohri, International President, Tilray Brands, said: “At Tilray Medical, we believe that every patient deserves access to safe, consistent, pharmaceutical-grade cannabis products. The launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines around the world. We want pharmacists and patients to help shape the future of responsible access, advance medical education and provide high-quality treatment options that improve lives.”

The launch supports the Panamanian medical cannabis framework established by Law 242 of 2021 and follows important regulatory advances made by the Ministry of Health, including No. 0406 of May 12, 2026. The decision, which established the main conditions for the admission of patients. The Ministry also recently introduced the System for the Identification of Medical Cannabis Users and Authorized Caregivers (SIUCMAA), creating a structured way to authorize medical practitioners and register patients.

Manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use in patients with qualified medical conditions permitted under Panamanian law, where permitted. The products reflect Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.

Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP certified medical cannabis products to regulated markets worldwide. The platform enables Tilray Medical to effectively support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.

For more information:
Tilray
www.tilray.com

Continue Reading

Cannabis News

Medical Marijuana Is ‘Effective’ In Providing Relief To Patients With Restless Legs Syndrome, Study Shows

Published

on

By

People with restless leg syndrome (RLS) may find “significant” long-term relief with cannabis treatment, according to a new study.

While dopamine agonists have traditionally been the “first-line treatment” for RLS, recent studies indicate that gabapentinoids are now being recommended, the researchers said. Because cannabinoids, like gabapentinoids, inhibit a certain type of amino acid associated with the disorder, scientists decided to test their therapeutic effectiveness.

The open-label exploratory study, conducted by European researchers at the University of Madrid and published in the Journal of Neurology, found that a cannabis product containing 2.7 mg of THC and 2.5 mg of CBD was “effective in reducing RLS severity” among patients with multiple sclerosis and “associated idiopathic RLS.”

“Improvements were observed after 1 to 3 months of treatment and were maintained after 1 year among patients who continued therapy,” the study of 18 patients with RLS showed. For those who remained in treatment after a year, 67 percent “continued to show sustained improvement.”

The the findings it may not be surprising that cannabis in particular is known to reduce the severity of muscle spasms and related conditions, but its effectiveness for RLS is remarkable given that no state specifically lists it as a condition for medical cannabis.

Of course, RLS can be a symptom of other general disorders like multiple sclerosis, and some states give doctors more latitude to make recommendations for medical marijuana for any condition they see fit.

In any case, research outside of Spain could be based on research into alternative treatment options that could replace dopamine agonists in the treatment of restless legs syndrome.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Wyoming AG keeps cannabis on Schedule I, rejects federal reclassification

Published

on

By











Wyoming Attorney General Keith Kautz announced on July 7 that he would keep all marijuana products in Schedule I of Wyoming’s Controlled Substances Act, refusing to align the state’s cannabis policy with the federal reorganization order issued earlier this year.

Kautz, who also serves as Wyoming’s drug and substance abuse commissioner, held a public hearing on June 18 after filing an objection to aligning the state’s cannabis schedule with a federal amendment on May 27. State law requires the commissioner to give interested parties an opportunity to be heard after that objection, but only nine people responded. Four email comments supported leaving cannabis as a Schedule I drug, four as Schedule III. It was approved for use and one person attended the hearing to request that cannabis remain in Schedule I.

His decision follows an April 2026 order signed by U.S. Attorney General Todd Blanche that bans state-licensed medical cannabis, FDA-approved cannabis products, cannabis extracts and naturally derived delta-9 THC III.

Kautz’s office says: “After consideration of all stakeholder comments, the commissioner has determined that all marijuana products, including marijuana subject to the state’s medical marijuana license, will remain in Schedule I of the Wyoming Controlled Substances Act.”

His announcement adds, “The decision to reschedule medical marijuana and marijuana products is an important policy decision that is best left to the Wyoming Legislature and should not be made through administrative rule.”

Wyoming remains one of eight states without a medical cannabis program. A December 2020 poll by the University of Wyoming’s Wyoming Center for Polling and Analysis found that 85 percent of state residents support legalizing medical cannabis, despite a failed 2024 ballot initiative effort. Possession of three ounces or less carries up to 12 months in prison under current state law, and selling any amount is punishable by up to 10 years in prison and a $10,000 fine.

Kautz says his office will “properly schedule products approved by the United States Food and Drug Administration once that agency has approved the product,” pointing to the Schedules II and III listings of Cesamet and Dronabinol as evidence that the state complies with federal cannabinoid drug law.










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media